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Abstract. Survivin (SVV) is a protein that belongs to 
the inhibitor of apoptosis proteins (IAP) family and is 
involved in the G2/M phase progression of the cell cycle as 
a spindle-associated molecule. The biological features of 
this protein are well documented and its activity appears to 
be involved in mitochondria-dependent and -independent 
antiapoptotic pathways. Overexpression of SVV at the tran-
scriptional and translational level has been associated with 
cancer, a multifactorial disorder in which the occurrence 
of a -31G to C polymorphism in the promoter region may 
significantly contribute to the development of this pathology. 
To verify this hypothesis, the occurrence of a single nucleo-
tide polymorphism (SNP) in cis-acting cell cycle-dependent 
elements (CDEs) and in cell cycle homology regions (CHRs) 
of the survivin TATA-less promoter was investigated. A total 
of 23 oral squamous cell carcinoma (OSCC) cell lines and 
normal epithelium-derived normal human epidermal kerati-
nocyte (NHEK) cell lines were analyzed by RFLP and direct 
DNA sequencing of their promoter region. Furthermore, 
survivin expression at the transcriptional and translational 
levels was evaluated in these cells by RT-PCR and Western 
blotting, respectively. The findings indicate that the presence of a 
G or C allele is not directly correlated to survivin expression, 
at the mRNA or at the protein level, at least in the OSCC lines 
analyzed in this study.
Introduction
Survivin was discovered by Altieri's group in 1997 (1). The 
gene coding for survivin was also identified by the same 
group during a search for the unknown receptor (effector cell 
protease receptor, epr-1) of blood coagulation factor Xa (2).
Survivin is an essential protein that acts as a passenger 
protein involved in cell division, and belongs to the inhibitor 
of apoptosis proteins (IAP) family (1-3). Its antiapoptotic 
zinc-binding domain, baculoviral IAP repeat (BIR), was iden-
tified for the first time in a baculoviral protein (4). The human 
locus is indicated as BIR-containing 5 (BIRC5) and lies on 
the long arm of chromosome 17 in the telomeric region 25 
(17q25) (5). This locus is the source of numerous variant 
transcripts (survivin, survivin-1α, survivin-2α, survivin-2β, 
3β and Δ3), where survivin is the most abundantly transcribed 
and translated variant in a 142 amino acid-long polypeptide, 
whereas the minor variants are poorly expressed and investi-
gated (6-9). Furthermore, the occurrence of a natural survivin 
antisense strand, defined as a distinct gene, codifying for 
a hypothetical receptor of Xa coagulation factor, epr-1, is 
well documented (2-10). All of the splicing isoforms share 
a common promoter belonging to the housekeeping family 
promoter that is known to be TATA-less and CpG-rich (11).
The survivin promoter region was investigated and the 
minimal promoter region, detected within the proximal 
-220 nt of the human survivin gene, was found to contain 
numerous Sp1 sites, three cell cycle-dependent elements 
(CDEs) and one cell cycle homology region (CHR) implicated 
in G1 transcriptional repression in a number of S/G2- 
regulated genes (11,12). Xu et al refined the map of the regu-
latory consensus sequences by identifying two other CDEs 
flanking the unique CHR box, indicated as CDE1 and CDE2. 
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In the latter, these authors highlighted the outcome of the 
G/C single nucleotide polymorphism (SNP) at position -31 (13). 
The rationale was that this repressor ligand zone binds the 
putative repressor complex with different affinity depending 
on whether G or C lies in position -31. Studies by these authors, 
performed on cancer-derived or normal cell lines, showed that 
the presence of the C allele was associated with normal cell 
lines, whereas the G allele was related to cancer. Subsequently, 
by using a luciferase reporter gene construct transfected 
in normal breast MCF-10A and cancer MDA-MB221 cell 
lines, Xu et al demonstrated that the -31G survivin promoter 
upstream of the reporter gene was more effective in stimu-
lating gene expression at all cell cycle stages, even though 
the greatest effect was found, as expected, in the G2/M phase 
(13). These data suggest that the presence of G at position -31 
derepresses survivin gene transcription, favoring the cancer 
phenotype.
Successive studies, performed in cancer-bearing patients, 
indicate that the negative and positive risk of cancer is asso-
ciated with the -31C/G polymorphism (14-16). In particular, 
where the association with SNP was positive, the -31C allele 
appears to be related to increased cancer risk, which is in 
contrast to the results by Xu et al.
On the basis of these data and considerations, we analyzed 
a possible correlation between the -31G/C SNP and survivin 
expression in various oral squamous cell carcinoma (OSCC) 
cell lines in comparison to a normal human epidermal kerati-
nocyte (NHEK) epithelial cell line.
Materials and methods
Cell cultures. The cell lines shown in Table I were grown in 
the recommended media at 37˚C in a humidified atmosphere 
of 5% CO2. NHEK cells were obtained from Lonza (Lonza, 
Switzerland), cultured in Clonetics® KGM complete medium 
(Lonza), and utilized up to the fourth passage. After washing 
with phosphate-buffered saline (PBS), the cultured cells were 
harvested with a cell scraper, and centrifuged at 2,000 rpm for 
10 min. The cell pellets were stored at -80˚C prior to protein, 
RNA and genomic DNA isolation. The NHEK cell line was 
derived from normal epithelium.
Extraction, amplification and sequencing of the survivin 
promoter region. Genomic DNA was isolated using a DNA 
microextraction kit (Stratagene, La Jolla, CA, USA) according 
to the manufacturer's instructions. The PCR was carried out 
in 40 µl master mixture containing 10% DMSO for extension 
through the GC-rich region. The thermal cycling process 
included initial denaturation at 95˚C for 10 min, followed by 
35 cycles (denaturation at 94˚C for 45 sec, annealing at 60˚C 
for 45 sec, and extension at 72˚C for 1 min). Sequencing was 
performed at 5 µl (Primm, Naples, Italy), and 30 µl were used 
for restriction fragment length polymorphism (RFLP) as 
described in the following paragraph.
Restriction fragment length polymorphism. The PCR prod-
ucts were subjected to electrophoresis on a 2% agarose gel. 
The 315 bp amplimers were extracted and then digested with 
the restriction enzyme MspI (New England Biolabs, MA, 
USA) at 37˚C for 1 h. Digestion patterns were analyzed by 
electrophoresis in a 3% ethidium bromide-stained agarose 
gel. The G allele was cleaved by the restriction enzyme MspI, 
generating a 190 and a 125 bp-long fragment (upper band, U, 
and middle band, M), whereas the cleaved C allele generated 
3 fragments, two of which were 120 and 125 bp long, comi-
grating as a middle band (M band) and the third one, 70 bp 
long, as a lower band (L band). The heterozygote G + C gener-
ated a G and C digestion pattern showing a mixture of U, M 
and L bands (Fig. 1A).
Western blot analysis. Cell pellets were suspended in lysis buffer 
(~5x106/ml) containing 50 mM Tris HCl, 2% sodium dodecyl 
sulfate (SDS) and 10% glycerol for 15 min in ice-cold water, 
and heated twice to 95˚C for 3 min. Lysates were microfuged at 
room temperature for 10 min and supernatants were collected. 
Protein concentration was measured using Bradford's method 
(Sigma-Aldrich, St. Louis, MO, USA). Proteins (50 µg/
lane) were electrophoresed on 15% SDS-polyacrylamide 
gels and transferred to nitrocellulose membranes (Bio-Rad 
Laboratories, Hercules, CA, USA). Immunoreactive proteins 
were detected by chemiluminescence (SuperSignal West Pico, 
Pierce Chemical Co., Rockford, IL, USA) according to the 
manufacturer's instructions using Hyperfilm ECL (Amersham 
Biosciences, Piscataway, NJ, USA). Semi-quantitative values of 
proteins were measured by densitometry of Western blotting 
using β-actin as an internal control.
Table I. Survivin promoter polymorphism, mRNA and protein 
in OSCC cell lines.
Cell line Polymorphism mRNAs  Proteins
 at site -31
NHEK  G/G 0.08 0.04
CAL33 G/G 0.38 0.17
OSC30  G/G 0.38 0.64
KM2  G/G 0.37 0.50
HSC4  G/G 0.46 0.85
KM5  G/G 0.54 0.18
KM4  G/G - 0.37
OSC19  G/G 0.36 0.18
HNT  G/G 0.40 0.28
KM1  G/G 0.33 0.36
KM3  G/G 0.44 0.90
PE34  G/G - -
PE46  G/G - -
PE41  G/C - -
HSC3 G/C 0.42 0.10
HEP2 G/C 0.39 2.31
HSC2 G/C 0.42 0.39
KB G/C 0.51 -
OSC20 C/C 0.31 0.40
CAL27 C/C 0.47 0.40
TYS C/C 0.51 0.36
HSG C/C 0.43 1.09
HN C/C 0.39 0.62
Ca9-22 C/C 0.27 0.19
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RT-PCR analysis. Total RNA was isolated from 5x106 cells 
by TRIzol reagent (Invitrogen, Inc., Carlsbad, CA, USA). 
Total RNA (300 ng) was used for RT-PCR, using the 
SuperScript III One-Step RT-PCR kit (Invitrogen). Full-length 
specific primers were 5'-GACCACCGCATCTCTACATTC-3' 
(forward) and 5'-TGC TTTTTATGTTCCTCTATGGG-3' 
(reverse). GAPDH was used as a housekeeping gene: 5'-TTG 
GTATCGTGGAAGGACTCA-3' (forward) and 5'-TGTCATC 
ATATTTGGCAGGTTT-3' (reverse). RT-PCR conditions were 
as follows: reverse transcription at 55˚C for 30 min, termi-
nated by 94˚C for 2 min and followed by 35 cycles of 
denaturation for 15 sec at 94˚C, annealing for 30 sec at 55˚C 
and extension for 1 min at 68˚C. The final extension was 
carried out at 68˚C for 5 min. Semi-quantitative analysis of 
mRNA was performed by densitometry of RT-PCR amplifica-
tion products using GAPDH as an internal control.
Statistical analysis. Statistical analysis was carried out using the 
two-way ANOVA test, followed by a post-hoc (Newman-Keuls) 
test to form multiple comparisons. P<0.05 was considered to be 
statistically significant: p<0.05, p<0.01, p<0.001.
Results
The -31C/G polymorphism in the OSCC survivin promoter is 
significantly related to cancer phenotype. The characterization 
of the G/C polymorphism at position -31 of the survivin 
promoter was evaluated by RFLP and direct DNA sequencing 
in 22 OSCC cell lines and in one NHEK cell line. The results 
are shown in Table I, and indicate that the -31G polymorphism 
in the OSCC survivin promoter is significantly (73% of 
G alleles vs. 37% of C alleles) correlated to the cancer pheno-
type, as previously reported by Xu et al (13).
Survivin mRNA expression is not associated with the -31C/G 
polymorphism and is always higher in OSCC as compared 
to NHEK cell lines. The mRNA survivin level, as evaluated 
by densitometry, was similar in the GG and CC genotypes 
(Table I). The values obtained do not suggest any significant 
association with the -31G/C polymorphism, although the 
amount of survivin mRNA was always higher in the OSCC 
cell lines as compared to the NHEK ones. The results obtained 
suggest that the survivin promoter polymorphism at posi-
tion -31 is not associated with survivin expression, at least in 
the OSCC cell lines analyzed.
Protein levels of survivin do not correlate with the -31G/C 
polymorphism and survivin is always overexpressed in OSCC 
as compared to NHEK cell lines. The protein level of survivin, 
as analysed by Western blotting and quantified by densitom-
etry, was similar in the GG and CC genotypes in 20 OSCC 
cell lines (Table I), although the amount of survivin protein 
was always found to be higher in OSCC cell lines than in 
NHEK ones. The data are consistent with a direct involvement 
of protein expression in the cancerous phenotype; however, 
no correlation was found between expression and G/C poly-
morphism. Moreover, the protein expression was varied when 
correlated to the mRNA expression (Fig. 2).
Discussion
In the present study, we examined polymorphisms in the 
promoter of the survivin gene at position -31, in 22 OSCC 
and NHEK cell lines. The association between -31G/C SNP 
and survivin expression was investigated. The -31G allele 
occurred in 63% (22 OSCC: 12 GG, and 5 GC and 6 CC) of 
the oral cancer cells analyzed (Fig. 1). These results were in 
line with the findings of two other authors who demonstrated 
that the G allele was present in 70% (22 different carcino-
matous cell lines: 15 GG, 6 CC and 1 GC) and 75% (12 cell 
lines: 7 GG, 1 CC and 4 GC) of the cancer cell lines analyzed 
(13,18). In order to explore whether this polymorphism was 
  A
  B
Figure 1. -31G/C polymorphism of PCR- amplified SVV promoter DNA. 
(A) RFLP profile of the polymorphic pattern obtained by electrophoretic 
analysis (see Materials and methods). (B) Direct sequencing analysis of the 
survivin promoter: arrows indicate the -31 position of the G/G, C/C or G/C 
polymorphism.
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associated with survivin expression, the expression was inves-
tigated using RT-PCR and Western blotting (Fig. 2). The data 
obtained do not confirm any direct relationship between the 
G (or C) allele at position -31 and enhanced mRNA expression 
(see Table I). In addition, consistent with our previous data 
on oral cancer patients, the mRNA expression was always 
significantly higher in OSCC cells than in normal tissues (21). 
Similar results were obtained by other authors using breast 
cancer cells and MCF-10A normal cells as controls (18).
The -31G/C polymorphism was also investigated in human 
epidemiological studies to determine whether there was any 
possible association between this polymorphism and cancer 
development. Association with cancer risk has been demon-
strated in lung carcinoma (Korea), sporadic colorectal cancer 
(Greece), urothelial carcinoma (Taiwan) and gastric carcinoma 
(China). When an association was found, cancer risk was 
always correlated to the C allele. In contrast, no association 
was detectable in acute myeloid leukemia (Germany), cervical 
cancer (Hungary), breast cancer (France) and esophageal 
SCC (China) (14-19). Concerning sporadic colorectal cancer, 
urothelial carcinoma and epithelial SCC, a positive correla-
tion between -31C SNP and cancer risk was found when the 
clinical and pathological grade of the tumor was taken into 
consideration (15,16,19,20).
In conclusion, we believe that in defined human popula-
tions the -31C allele dependence of the survivin expression in 
certain tumors may be associated with cancer risk, although 
more studies, particularly population-based studies, are 
required to elucidate the role of survivin in cancer develop-
ment.
Figure 3. Mapping of a putative transcription factor for consensus sequences in the proximal promoter of the survivin gene.
Figure 2. Survivin expression in OSCC cell lines. (A) Survivin mRNA expression as evaluated by RT-PCR. (B) Survivin protein expression as assessed by 
Western blot analysis. The histograms (left panel) show the semi-quantitative values of mRNA and protein normalized with GAPDH, and β-actin used as 
reporter genes (right panel), respectively.
  A
  B
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